Citius Oncology (CTOR) Change in Account Payables (2023 - 2026)

Citius Oncology (CTOR) has reported Change in Account Payables for 4 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Account Payables fell 26.88% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $3.9 million (up 70.18% YoY), while the FY2025 annual figure was $9.5 million, down 33.27% from the prior year.
• Change in Account Payables climbed to $1.5 million in Q1 2026 per CTOR's latest filing, from -$2.8 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $4.6 million in Q3 2025 and bottomed at -$2.8 million in Q4 2025.
• Historically, Change in Account Payables has averaged $563619.2 across 4 years, with a median of $602939.0 in 2025.
• On a YoY basis, Change in Account Payables climbed as much as 360.51% in 2025 and fell as far as 220.81% in 2025.
• Citius Oncology's Change in Account Payables stood at -$1.1 million in 2023, then jumped by 312.87% to $2.3 million in 2024, then tumbled by 220.81% to -$2.8 million in 2025, then surged by 153.64% to $1.5 million in 2026.
• Business Quant data shows CTOR's Change in Account Payables at $1.5 million in Q1 2026, -$2.8 million in Q4 2025, and $4.6 million in Q3 2025.